Everything Genetic Multi-Cancer Panel

Understand your cancer risk with this comprehensive hereditary cancer test, looking into specific genes associated with an increased likelihood of developing 12 different types of cancer.

Buy now

Genetic testing for understanding hereditary cancer risk

Whether you have a personal or family history of cancer, this test is a powerful tool to help you understand your personal risk.

Armed with this genetic information, you and your healthcare provider can make informed choices to lower your risk of hereditary cancers, including breast, colorectal, ovarian, prostate, and more.

Your options may include regular screening, risk reducing medication, or even considering surgery earlier to reduce your cancer risk.

Certain genetic variants can run in families, so if you have a genetic variant, there’s a 50% chance your parents, children, or siblings might have it too.

Understanding this hereditary risk is important, prompting your family members to consider getting tested as well. This proactive step can lead to early detection and preventative measures for those at risk.

Why choose the Everything Genetic Multi-Cancer Panel?

Comprehensive gene panel – providing assurance that potential gene variants are identified for informed healthcare decisions.
Hereditary cancer test – helping to identify at-risk family members for genetic testing and preventative actions.
Accelerated turnaround time – allowing prompt action with your healthcare provider to reduce cancer risk and improve treatment effectiveness.
Pre and post-test clinical support – ensures informed decision-making before taking a genetic test and understanding your personalised results report after the test.

Download a copy of our patient information leaflet here >>

Diseases tested►Close tab

Hereditary Breast and Ovarian Cancer (HBOC) – BRCA1, BRCA2 and PALB2
Other moderate risk breast cancer genes – ATM, CHEK2, BARD1 and NF1
Other moderate risk HBOC genes – RAD51C and RAD51D
Other moderate risk ovarian genes – BRIP1
Li-Fraumeni Syndrome – TP53
Cowden Syndrome – PTEN
HNPCC (Lynch Syndrome) – MLH1, MSH2, MSH6, PMS1 and PMS2
Familial Adenomatous Polyposis (also MUTYH if homozygous) – APC
Juvenile Polyposis – BMPR1A, SMAD4
Peutz-Jeghers Syndrome – STK11
Other bowel cancer genes – POLE and POLD1
hereditary diffuse gastric cancer (and lobular breast cancer) – CDH1
Von Hippel-Lindau – VHL
Multiple Endocrine Neoplasia – MEN1 and RET
Gorlin Syndrome – PTCH1
Paraganglioma predisposition – SDHB and SDHD
Melanoma genes – CDKN2a, CDK4 and MITF

Genes tested for►Close tab

ABRAXAS1; APC; ATM; AXIN2; BAP1; BARD1; BLM; BMPR1A; BRCA1; BRCA2; BRIP1; CDH1; CDK4; CDKN2A; CHEK2; DICER1; DIS3L2; EPCAM; FANCC; FH; FLCN; GALNT12; HNF1A; HNF1B; HOXB13; KIT; MC1R; MEN1; MET; MITF; MLH1; MLH3; MRE11; MSH2; MSH3; MSH6; MUTYH; NBN; NF1; NTHL1; PALB2; PMS1; PMS2; POLD1; POLE; POT1; PRSS1; PTCH1; PTEN; RAD50; RAD51C; RAD51D; RECQL; RET; RNF43; RPS20; SDHA; SDHAF2; SDHB; SDHC; SDHD; SMAD4; SMARCA4; STK11; TGFBR2; TP53; TSC1; TSC2; VHL; WT1; XRCC2; XRCC3

Test results►Close tab

A personalised results report will be sent to you and made available to your clinician (with your consent).

There are three possible result outcomes from this test:

A variant detected result – a pathogenic or likely pathogenic variant has been detected
A Variant of Uncertain Significance (VUS) result
A negative result – no pathogenic variant detected

Variant detected: A positive result means that a fault in one or more of your genes has been found. Therefore, you have an increased risk of developing the cancer related to that gene fault.

View a copy of a sample report here >>

Negative: A negative result means that the test has not identified any faults in the genes analysed. So, you have no variants in the genes analysed that put you at risk of developing the hereditary cancers tested for.

View a copy of a sample report here >>

Variant of Uncertain Significance: The test could report a Variant of Uncertain Significance, also known as a VUS. This means that the test has identified a change in the sequence of one or more of your genes, but it is not yet known if that indicates a clinically significant cancer risk. However, it is unusual to receive a VUS result on any of the genes analysed by this test.

View a copy of a sample report here >>

No personal medical guidance is provided with the test result. This should be obtained directly from a clinician.

Ordering information►Close tab

Who can order this test from Everything Genetic? Healthcare providers, individuals, and patient referrals.

Turnaround time: 2 – 3 weeks from receipt of sample in laboratory [1]

Preferred specimen: Non-invasive simple saliva sample using Oragene OG-610.

Alternative specimen collection: Blood using an EDTA purple top tube (we accept both K2EDTA and K3EDTA). Minimum volume requirement is 3mL for a 10mL tube and 2mL for a 4mL or 6mL tube.

Delivery information: Test kits will be sent out by using a Royal Mail Tracked service, unless otherwise arranged.

[1] MLPA performed on all suspected CNVs may require a longer turnaround time.

Pre and post test clinical support►Close tab

Pre and post-test clinical support is mandatory for those taking the test. This can either be provided by your chosen clinician or Everything Genetic’s medical team.

This unique and personal clinical support service offered by Everything Genetic provides you and your relatives the guidance and support you need to help understand your results and what you should do next.

Everything Genetic’s pre-test clinical support is provided through a clinically guided informational video which explains:

What the test is for
Why patients should take the test
What it does and doesn’t test for
What the possible results are from taking the test

If the results show a negative or VUS result, you will receive a clinically guided information video explaining what the results mean and what you should do next. A results report will also be sent to you and/or clinician via email, with the option of speaking to our medical team.

If the results show a variant detected result, a private consultation will be arranged with either our medical team or the clinician who referred you. Following the consultation, a results report will be sent via email.

For clinicians who provide their own pre and post-test clinical support, the results will be sent directly to them.

Read more about our pre and post-test clinical support service >>

Clinical description►Close tab

Genetic testing for hereditary cancer risk involves analysing an individual’s DNA to identify specific gene variants associated with an increased likelihood of developing certain types of cancer.

This type of testing helps assess an individual’s inherited susceptibility to cancer based on their genetic makeup.

By understanding these genetic factors, individuals and healthcare providers can make informed decisions about preventative measures, early detection, and personalised treatment strategies to help reduce their risk of cancer. It also allows for the identification of at-risk family members who may benefit from similar testing and proactive health management.

Each gene in the Everything Genetic Multi-Cancer Panel has been carefully selected based on its risk potential in the development of one or more of the following cancers: breast, colorectal, endometrial, gastric, melanoma, ovarian, pancreatic, prostate, renal, skin, thyroid, and uterine.

If you have a genetic variant, your parents, children, and siblings have a 50% chance of having the same variant.

If an individual has a faulty gene, it doesn’t mean that they will develop cancer. It does mean, however, that they are a higher risk than others. Genetic specialists estimate that between 5 – 10% of cancers diagnosed are linked to an inherited gene fault.

It is important to remember that cancers are not only caused by hereditary gene faults: lifestyle, environment and age can all play a part.

Cancer risk and incidences

Breast cancer: Breast cancer is the most common cancer in the UK, accounting for 56,987 cases in 2019. The general population risk of breast cancer for women in the UK is 1 in 7. Approximately 5 – 10% of breast cancer cases are due to an inherited gene fault.

Colorectal cancer: Colorectal cancer is the 4^th most common cause of cancer in the UK, accounting for 44,706 cases in 2019. The general population risk of bowel cancer for men in the UK is 1 in 15. The general population risk of bowel cancer for women in the UK is 1 in 18. Approx. 5 – 10% of bowel cancer cases are due to an inherited gene fault.

Womb cancer; Womb cancer is the 4^thmost common cause of cancer in women the UK, accounting for over 9,700 cases every year. The general population risk of womb cancer for women in the UK is 1 in 15. Less than 5% of womb cancer cases are due to an inherited gene fault.

Gastric cancer: Gastric cancer is the 17^th most common cancer in the UK, accounting for 6,550 cases between 2016-18. The general population risk of gastric cancer for men in the UK is 1 in 76. The general population risk of gastric cancer for women in the UK is 1 in 130. Approx. 1-3% of gastric cancer cases are due to an inherited gene fault.

Melanoma cancer: Melanoma cancer is the 5^th most common cancer in the UK, accounting for 17,845 cases in 2019. The general population risk of melanoma cancer for men in the UK is 1 in 36. The general population risk of melanoma cancer for women in the UK is 1 in 47. Approx. 10% of melanoma cancer cases are due to an inherited gene fault.

Ovarian cancer: Ovarian cancer is the 15^th most common cancer in the UK, accounting for 6,969 cases in 2019. The general population risk of ovarian cancer for women in the UK is 2 in 100 (2%). Approx. 20% of ovarian cancer cases are due to an inherited gene fault.

Pancreatic cancer: Pancreatic cancer is the 9^th most common cancer in the UK, accounting for 11,031 cases in 2019. The general population risk of pancreatic cancer for men in the UK is 1 in 53. The general population risk of pancreatic cancer for women in the UK is 1 in 57. Approx. 5 – 10% of pancreatic cancer cases are due to an inherited gene fault.

Prostate cancer: Prostate cancer is the 2^nd most common cancer in the UK, accounting for 55,068 cases in 2019. The general population risk of prostate cancer for men in the UK is 1 in 6. Approx. 5 – 9% of prostate cancer cases are due to an inherited gene fault.

Renal cancer: Renal cancer is the 8^th most common cancer in the UK, accounting for 12,050 cases in 2019. The general population risk for renal cancer for men in the UK is 1 in 34. The general population risk for renal cancer for women in the UK is 1 in 61. Approx. 3 – 5% of renal cancer cases are due to an inherited gene fault.

Skin (non-melanoma) cancer: Non melanoma skin cancer is the most common cancer in the UK, accounting for 155,985 cases in 2016-18. 1 in 36 UK males and 1 in 47 UK females will be diagnosed with melanoma skin cancer in their lifetime. Most non melanoma skin cancers don’t run in families. But research has found some families seem to have a higher number than normal. You have an increased risk of developing a squamous cell skin cancer (SCC) if one of your parents has had a SCC. People who have a family history of melanoma have an increased risk of basal cell skin cancer (BCC).

Thyroid cancer: Thyroid cancer is the 20^th most common cancer in the UK, accounting for 3,865 cases between 2016 – 18. The general population risk of thyroid cancer for men in the UK is 1 in 332. The general population risk for women in the UK is 1 in 170. Approx. 25% of thyroid cancer cases are due to an inherited gene fault.

Uterine cancer : Uterine cancer is the 11^h most common cancer in the UK, accounting for 10.021 cases in 2019. The general population risk of uterine cancer for women in the UK is 1 in 36.

Limitations

The genetic results are interpreted in the context of the provided clinical findings, family history, and other laboratory data. Misinterpretation of results may occur if the provided genetic data or patient information is inaccurate and/or incomplete. If the obtained genetic results are not compatible with the clinical findings, additional testing should be considered.

More complex genetic events such as inversions, translocations, and repeat expansions, are not analysed in this test. In addition, due to technology limitations, certain regions may be poorly covered, or not covered at all. In these regions and others encompassing repetitive, high homology (such as pseudogene homology), and GC-rich sequences, relevant variants can be missed.

The Copy Number Variation (CNV) detection software has a sensitivity of more than 95% for all homozygous/hemizygous deletions, as well as heterozygous deletions/duplications and homozygous/hemizygous duplications spanning at least three consecutive exons. Sensitivity of more than 90% for CNV calling is expected including for single exon. The CNV detection sensitivity is decreased for repetitive and homologous regions, such as pseudogenes. Heterozygous CNVs spanning less than three exons cannot reliably be detected. In cases with low quality DNA, CNV analysis may not be possible to perform.

Potential aberrant splicing is assessed with splice prediction tools. Intronic variants that are beyond 10 nucleotides from exon-intron boundaries are not considered for aberrant splicing analysis, with the exception of known pathogenic splicing variants evidenced by external sources.

References: